Analyst Rating Update on INC Research Holdings (INCR)

INC Research Holdings (INCR) : The consensus on INC Research Holdings (INCR) based on 9 analyst recommendation on the company stock is 1.78, which is interpreted as a Buy recommendation. Zacks Investment Research has issued a rank of 2 which endorses a Buy on the stock. However, 5 brokers have a differing view as they consider the stock to be a Strong Buy at current levels. 1 analyst believes that the stock is a Buy, which can produce decent returns in the future. 3 experts consider that the stocks earnings and the quoted price is in harmony, hence, they give it a Hold rating.

INC Research Holdings (INCR) : The consensus price target for INC Research Holdings (INCR) is $50.83 for the short term with a standard deviation of $3.54. The most optimist securities analyst among the 6 who monitor the stock believes that the stock can reach $56, however, the pessimist price target for the company is $47.

For the current week, the company shares have a recommendation consensus of Buy.


INC Research Holdings (NASDAQ:INCR): During Wednesdays trading session, Bulls were in full control of the stock right from the opening. The stock opened at $42.81 and $42.73 proved to be the low of the day. Continuous buying at higher levels pushed the stock towards an intraday high of $44.58. The buying momentum continued till the end and the stock did not give up its gains. It closed at $44.52, notching a gain of 3.57% for the day. The total traded volume was 806,336 . The stock had closed at $42.99 on the previous day.

INC Research Holdings, Inc. is a global contract research organization (CRO). The Company is focused on Phase I to Phase IV clinical development services for the biopharmaceutical and medical device industries. The Companys segment Clinical Development Services offers a variety of clinical development services, including global studies, clinical monitoring, investigator recruitment, patient recruitment, data management and study reports. The Companys segment Phase I Services focuses on clinical development services for Phase I trials that include scientific exploratory medicine, first-in-human studies through proof-of-concept stages and support for Phase I studies in established compounds. The Companys segment Global Consulting provides consulting services regarding clinical trial regulatory affairs, regulatory consulting services, quality assurance audits and pharmacovigilance consulting, non-clinical consulting and medical writing consulting.

Comments (0)

Leave a Reply

Your email address will not be published. Required fields are marked *

Get Pre-Market Alerts!

Get Pre-Market Analysts' Upgrades, Downgrades, Earnings & Initiations with our FREE daily email newsletter.